Circulating serotonin, catecholamines, and central nervous system circuitry related to some cardiorespiratory, vascular, and hematological disorders

Journal of Applied Research

Volumn 5, Issue 4, 2005, Pages 605-621

  Lechin, Fuad ^a   Van Der Dijs, Bertha ^a   Lechin, Alex E ^b  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b UNIVERSITY OF HOUSTON COLLEGE OF MEDICINE   (United States)

Author keywords

ANS assessment; Arterial hypertension; Bronchial asthma; Carcinoid syndrome; Chronic congestive heart failure; Idiopathic thrombocytopenic purpura; Platelet disorders; Polycythemia vera; Pulmonary hypertension

Indexed keywords

BUSPIRONE; CATECHOLAMINE; CENTRAL NERVOUS SYSTEM AGENTS; FENFLURAMINE; FLUOXETINE; IMIDAZOLINE; IMMUNOSUPPRESSIVE AGENT; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE;

ASTHMA; BRONCHOSPASM; CARCINOID SYNDROME; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CONGESTIVE HEART FAILURE; DRUG MECHANISM; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LUNG VASOCONSTRICTION; NEUROPHARMACOLOGY; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; POLYCYTHEMIA VERA; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; SEROTONIN BLOOD LEVEL; SEROTONIN UPTAKE; VASCULAR DISEASE;

EID: 33750692079     PISSN: 1537064X     EISSN: 1537064X     Source Type: Journal    
DOI: None     Document Type: Review

References (171)

1. Rausch JL, Janowsky DS, Risch SC, Huey LY. Physostigmin effects on serotonin uptake in human blood platelets. Eur J Pharmacol. 1985;109:91-96.
2. Vesifeld IL, Vasiljiev VN, Iljicheva RF. Relationship of catecholamines, histamine and serotonin in men under different kinds of stress. In: Usdin E, Kvetnansky R, Kopin IJ, eds. Catecholamines and Stress. Oxford, UK: Pergamon Press; 1976:527-528.
3. Larsson PT, Hjemdhal P, Olsson G, et al. Altered platelet function during mental stress and adrenaline infusion in humans: evidence for an increase aggregability in vivo as measured by filtragometry. Clin Sci. 1989;76:369-376.
4. Breier A, Albus M, Pickar D, et al. Controllable and uncontrollable stress in humans: alterations in mood and neuroendocrine and psychophysiological function. Am J Psychiatry. 1987;144:1419-1425.
5. Young JB, Rowe JW, Pallota JA, et al. Enhanced plasma norepinephrine response to upright posture and oral glucose administration in elderly human subjects. Metabolism. 1980;29:532-535.
6. Irwin M, Thompson J, Miller C, et al. Effects of sleep and sleep deprivation on catecholamines and interleukin-2 levels in humans: clinical implications. J Clin Endocrinol Metab. 1999;84:1979-1985.
7. Robertson D, Johnson GA, Robertson RM, et al. Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man. Circulation. 1979;59:637-643.
8. Lechin F, van der Dijs B, Lechin M, et al. Effects of an oral glucose load on plasma neurotransmitters in humans: involvement of REM sleep? Neuropsychobiology. 1992;26:4-11.
9. Lechin F, van der Dijs B, Lechin ME, et al. Plasma neurotransmitters throughout oral glucose tolerance test in non-depressed essential hypertension patients. Clin Exp Hypertens. 1993;15:209-240.
10. Lechin F, van der Dijs B, Lechin ME, et al. Plasma neurotransmitters, blood pressure and heart rate during supine-resting, orthostasis, and moderate exercise conditions in two types of hypertensive patients. Res Comm Biol Psychol Psychiatry. 1997;22:97-112.
11. Lechin F, Pardey-Maldonado B, van der Dijs B, et al. Circulating neurotransmitters during the different wake-sleep stages in normal subjects. Psychoneuroendocrinology. 2004;29:669-685.
12. Lechin F, van der Dijs B, Rada I, et al. Plasma neurotransmitters and cortisol in duodenal ulcer patients. Role of stress. Dig Dis Sci. 1990;35:1313-1319.
13. Lechin F, van der Dijs B, Jackubowitz D, et al. Effects of clonidine on blood pressure, noradrenaline, cortisol, growth hormone and prolactin plasma levels in low and high intestinal tone subjects. Neuroendocrinology. 1985;40:253-261.
14. Lechin F, van der Dijs B, Orozco B, et al. Plasma neurotransmitters, blood pressure and heart during supine-resting, orthostasis and moderate exercise in severely ill patients: a model of failing to cope with stress. P s y chother Psychosom. 1996;65:129-136.
15. Lechin AE, Varon J, van der Dijs B, Lechin F. Plasma catecholamines and indoleamines during attacks and remission on severe bronchial asthma: possible role of stress. Am J Respir Crit Care Med. 1994;149:778.
16. Lechin F, van der Dijs B, Vitelli G, et al. Psychoneuroendocrinological and immunological parameters in cancer patients: involvement of stress and depression. Psychoneuroendocrinology. 1990;15:435-451.
17. Lechin F, van der Dijs B, Orozco B, et al. Plasma neurotransmitters, blood pressure and heart rate during supine-resting, orthostasis and moderate exercise conditions in major depressed patients. Biol Psychiatry. 1995;38:166-173.
18. Lechin F, van der Dijs B, Jakubowicz D, et al. Effects of clonidine on blood pressure, noradrenaline, cortisol, growth hormone, and prolactin plasma levels in high and low intestinal tone depressed patients. Neuroendocrinology. 1985;41:156-162.
19. Lechin F, van der Dijs B, Jara H, et al. Effects of buspirone on plasma neurotransmitters in healthy subjects. J Neural Transm. 1998;105:561-573.
20. Lechin F, van der Dijs B, Lechin A, et al. The serotonin uptake-enhancing drug tianeptine suppresses asthmatic symptoms in children. A double-blind crossover placebo-controlled study. J Clin Pharmacol. 1998;38:918-925.
21. Lechin F, van der Dijs B, Orozco B, et al. Neuropharmacological treatment of bronchial asthma with an antidepressant drug: tianeptine. A double-blind crossover placebo-controlled study. Clin Pharmacol Ther. 1998;64:223-232.
22. Lechin F, van der Dijs B, Azocar J, et al. Stress, immunology and cancer: effect of psychoactive drugs. Arch Ven Farm Clin Terap. 1987;6:28-43.
23. Lechin F, van der Dijs B, Lechin A, et al. Doxepin therapy for postprandial symptomatic hypoglycaemic patients: neurochemical, hormonal and metabolic disturbances. Clin Sci (Lond). 1991;80:373-384.
24. Ahlman H, Bhargava HN, Dahlstrom A, et al. On the presence of serotonin in the gut lumen and possible release mechanisms. Acta Physiol Scand. 1981;112:263-269.
25. Burks TF, Long JP. Catecholamine-induced release of 5-hydroxytryptamine from perfused vasculature of isolated dog intestine. J Pharm Sci. 1966;55:1383-1386.
26. Larsson I, Ahlman H, Bhargava HN, et al. The effects of splanchnic nerve stimulation on the plasma levels of 5-HT and SP in the portal vein of the cat. J Neural Transm. 1979;46:105-112.
27. Kjellstrom T, Ahlman H, Dahlstrom A, Risberg B. The cellular uptake of 5-hydroxytryptamine in the rat lung in vivo - a histochemical study. Acta Physiol Scand. 1982;116:455-460.
28. Born GVR, Gillson RE. Studies on the uptake of 5-hydroxytryptamine by blood platelets. J Physiol (Lond). 1959;146:472-491.
29. Davis RB, Wang Y. Rapid pulmonary removal of 5-hydroxytryptamine in the intact dog. Proc Soc Exp Biol. 1965;118:799-800.
30. Gillis CN, Cronau LH, Mandel S, Hammond GL. Indicator dilution measurements of 5-hydroxytryptamine clearance by human lung. J Appl Physiol. 1979;46:1178-1183.
31. Lauweryns JM, van Ranst L, Lloyd RV, O'Connor DT. Chromogranin in bronchopulmonary neuroendocrine cells. Immunocytochemical detection in human, monkey, and pig respiratory mucosa. J Histochem Cytochem. 1987;35:113-118.
32. Keith IM, Will JA. Dynamics of the neuroendocrine cell - regulatory peptide system in the lung. Specific overview and new results. Exp Lung Res. 1982;3:387-402.
33. Moosavi H, Smith P, Heath D. The Feyrter cell in hipoxia. Thorax. 1973;28:729-741.
34. Johnson DE, Georgieff MK. Pulmonary neuroendocrine cells. Their secretory products and their potential roles in health and chronic lung disease in infancy. Am Rev Respir Dis. 1989;140:1807-1812.
35. Levitt RC, Mitzner W. Autosomal recessive inheritance of airway hyperreactivity to 5-hydroxytryptamine. J Appl Physiol. 1989;67:1125-1132.
36. Tobe T, Izumikawa F, Sano M, Tanak C. Release mechanisms of 5-HT in mammalian gastrointestinal tract - especially vagal release of 5-HT. In: Fujita T, ed. Endocrine Gut-Pancreas. Amsterdam, Netherlands: Elsevier; 1976:371-380.
37. Schworer H, Racke K, Kilbinger H. Cholinergic modulation of the release of 5-hydroxytryptamine from the guinea pig ileum. Naunyn Schmiedebergs Arch Pharmacol. 1987;336:127-132.
38. Lechin F, van der Dijs B, Lechin ME. Plasma neurotransmitters and functional illness. Psychother Psychosom. 1996;65:293-318.
39. Gronstad KO, Zinner MJ, Dahlstrom A. Vagal release of serotonin into gut lumen and portal circulation via separate control mechanisms. J Surg Res. 1987;43:205-210.
40. Lechin F, van der Dijs B, Amat J, Lechin ME. Neuroanatomical basis: the noradrenergic system. In: Lechin F, van der Dijs B, eds. Neurochemistry and Clinical Disorders: Circuitry of Some Psychiatric and Psychosomatic Syndromes. Boca Raton, FL: CRC Press; 1989:2-9.
41. Lokhandwala MF, Hedge SS. Cardiovascular dopamine receptors: role of renal dopamine and dopamine receptors in sodium excretion. Pharmacol Toxicol. 1990;66:237-243.
42. 2 receptors: a mechanism limiting excessive sympathic-adrenal discharge in humans. J Clin Endocrinol Metab. 1988;66:626-631.
43. Mercuro G, Gessa G, Rivano CA, et al. Evidence for a dopaminergic control of sympathoadrenal catecholamines release. Am J Cardiol. 1988;62:827-828.
44. Lechin F, van der Dijs B, Lechin E. Pharmacology of the autonomic nervous system imbalances. In: Lechin F, van der Dijs B, Lechin E, eds. The Autonomic Nervous System: Physiological Basis of Psychosomatic Therapy. Barcelona, Spain: Editorial Cientifico-Medica; 1979:119-150.
45. Lechin F, van der Dijs B, Amat J, Lechin ME. Neuroanatomical basis: the serotonergic system. In: Lechin F, van der Dijs B, eds. Neurochemistry and Clinical Disorders: Circuitry of Some Psychiatric and Psychosomatic Syndromes. Boca Raton, FL: CRC Press; 1989:10-12.
46. Lechin F, van der Dijs B, Lechin ME: Bronchial asthma and pulmonary hypertension. In: Lechin F, van der Dijs B, Lechin ME, eds. Neurocircuitry and Neuroautonomic Disorders. Reviews and Therapeutic Strategies. Basel, Switzerland: Karger; 2002:66-68.
47. Feldman PD. Electrophysiological effects of serotonin in the solitary tract nucleus of the rat. Arch Pharmacol. 1994;349:447-454.
48. McCann M, Hermann GE, Rogers RC. Nucleus raphe obscurus (nRO) influence vagal control of gastric motility in rats. Brain Res. 1989;486:181-184.
49. Jacobs BL, Fornal CA. Activity of brain serotonergic neurons in the behaving animal. Pharmacol Rev. 1991;43:563-578.
50. Sawchenko PE. Central connections of the sensory and motor nuclei of the vagus nerve. J Auton Nerv Syst. 1983;9:13-26.
51. Thurston CL, Helton ES. Effects of intravenous phenylephrine on blood pressure, nociception, and neural activity in the rostral ventral medulla in rats. Brain Res. 1996;717:81-90.
52. Miller AD, Nonaka S. Mechanisms of vomiting induced by the serotonin-3 receptor agonists in the cat: effect of vagotomy, splanchnicectomy or area postrema lesion. J Pharmacol Exp Ther. 1992;260:509-517.
53. Callera JC, Bonagamba LGH, Sevoz C, et al. Cardiovascular effects of microinjection of low doses of serotonin into the NTS of unanesthetized rats. Am J Physiol. 1997;272:R1135-R1142.
54. Ireland SJ, Tyers MB. Pharmacological characterization of 5-hydroxy-tryptamine-induced depolarization of the rat isolated vagus nerve. Br J Pharmacy. 1987;90:229-238.
55. Vertes RP, Fortin WJ, Crane AM. Projections of the median raphe nucleus in the rat. J Comp Neurol. 1999;407:555-582.
56. Thurston-Stanfield CL, Ranieri JT, Vallabhapurapu R, Barnes-Noble D. Role of vagal afferents and the rostral ventral medulla in intravenous serotonin-induced changes in nociception and arterial blood pressure. Physiol Behav. 1999;57:753-767.
57. Yusof APM, Coote JH. Patterns of activity in sympathetic postganglionic nerves to skeletal muscle, skin and kidney during stimulation of the medullary raphe area of the rat. J Auton Nerv Syst. 1988;24:71-79.
58. Farkas E, Jansen ASP, Loewy AD. Periaqueductal gray matter projection to vagal preganglionic neurons and the nucleus tractus solitarius. Brain Res. 1997;764:257-261.
59. Larsen PD, Zhong S, Gebber GL, Barman SM. Differential pattern of spinal sympathetic outflow in response to stimulation of the caudal medullary raphe. Am J Physiol Regul Integr Comp Physiol. 2000;279:R210-R221.
60. Li YW, Wesselingh SL, Blessing WW. Projections from rabbit caudal medulla to C1 and A5 sympathetic premotor neurons, demonstrated with phaseolus leucoagglutinin and herpes simplex virus. J Comp Neurol. 1992;317:379-395.
61. Behbehani MM. Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol. 1995;46:575-605.
62. Chen S, Aston-Jones G. Anatomical evidence for inputs to ventrolateral medullary catecholaminergic neurons from the midbrain periaqueductal gray of the rat. Neurosci Lett. 1995;195:140-144.
63. Gauthier P. Pressor responses and adrenomedullary catecholamines release during brain stimulation in the rat. Can J Physiol Pharmacol. 1981;59:485-492.
64. Benarroch EE, Balda MS, Finkielman S, Nahmod VE. Neurogenic hypertension after depletion of norepinephrine in anterior hypothalamus induced by 6-hydroxydopamine administration into the ventral pons: role of serotonin. Neuropharmacology. 1981;22:29-34.
65. Dampney RAL, Czachurski J, Dembowsky K, et al. Afferent connections and spinal projections of the pressor region in the rostral ventrolateral medulla of the cat. J Auton Nerv Syst. 1987;20:73-86.
66. Privitera PJ, Granata AR, Underwood MD, et al. C1 area of the rostral ventrolateral medulla as a site for the central hypotensive action of propranolol. J Pharmacol Exp Ther. 1988;246:529-533.
67. 2 receptor agonists increase spontaneous sympathetic nerve discharge. Eur J Pharmacol. 1988;151:113-116.
68. Funakoshi K, Kadota T, Atobe Y, et al. Serotonin-immunoreactive axons in the cell column of sympathetic preganlionic neurons in the spinal cord of the filefish Stephanolepis cirrhifer. Neurosci Lett. 2000;280:115-118.
69. Young JB, Rosa RM, Landsberg L. Dissociation of sympathetic nervous system and adrenal medullary responses. Am J Physiol. 1984;247:E35-E40.
70. Astier B, Kitahama K, Denoroy L, et al. Biochemical evidence for an interaction between adrenaline and noradrenaline neurons in the rat brainstem. Brain Res. 1986;397:333-340.
71. Lechin F, van der Dijs B, Lechin AE. Neural sympathetic activity in essential hypertension. Hypertension. 2004;44:e3-e4.
72. Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995;99:249-254.
73. Deuchar GA, Docherty A, MacLean MR, Hicks MN. Pulmonary hypertension secondary to left ventricular dysfunction: the role of nitric oxide and endothelin-1 in the control of pulmonary vascular tone. Br J Pharmacol. 2002;135:1060-1068.
74. Belohlávková S, Simák J, Kokesová A, et al. Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels. J Appl Physiol. 2001;91:755-761.
75. Strange JW, Wharton J, Phillips PG, Wilkins MR. Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clin Sci. 2002;102:253-268.
76. Humbert M, Labrune P, Sitbon O, et al. Pulmonary arterial hypertension and type-1 glycogen-storage disease: the serotonin hypothesis. Eur Respir J. 2002;20:59-65.
77. Lechin F, van der Dijs B, Lechin AE. Pulmonary hypertension, left ventricular dysfunction and plasma serotonin. Br J Pharmacol. 2002;137:937-938.
78. Lechin F, van der Dijs B. Serotonin and pulmonary vasoconstriction. J Appl Physiol. 2002;92:1363-1364.
79. Lechin F, van der Dijs B, Lechin AE. Plasma serotonin, pulmonary hypertension and bronchial asthma. Clin Sci. 2002;103:345-346.
80. Lechin F, van der Dijs B. Plasma serotonin, bronchial asthma and tianeptine. Clin Physiol. 2001;21:723-724.
81. Lechin F, Lechin AE, van der Dijs B. Tianeptine, plasma serotonin, and pulmonary hypertension. Lancet. 2003;361:87-88.
82. Gordon JL, Olverman JH. 5-Hydroxytryptamine and dopamine transport by rat and human blood platelets. Br J Clin Pharmacol. 1978;62:219-226.
83. Lingjaerde O, Kildemo O. Dopamine uptake in platelets: two different low-affinity, saturable mechanisms. Agents Actions. 1981;11:410-416.
84. McGinty DJ, Harper RM. Dorsal raphe neurons, depression of firing during sleep in cats. Brain Res. 1976;101:569-575.
85. MacCarley RW. REM sleep and depression, common neurobiological control mechanisms. Am J Psychiat.1982;139:5-13.
86. Lechin F, van der Dijs B: Slow wave sleep (SWS), REM sleep (REMS), and depression. Res Commun Psychol Psychiatr Behav. 1984;9:227-262.
87. Lechin F, van der Dijs B, Lechin ME. Central neurocircuitry functioning during the wake-sleep cycle. In: Lechin F, van der Dijs B, Lechin ME, eds. Neurocircuitry and Neuroautonomic Disorders. Reviews and Therapeutic Strategies. Basel, Switzerland: Karger; 2002:3-13.
88. Glavin GB. Selective noradrenaline depletion markedly alters stress responses in rats. Life Sci. 1985;37:461-465.
89. Lechin F, van der Dijs B, Benaim M. Stress versus depression. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20:899-950.
90. Richelson E. Pharmacology of antidepressants - characteristics of the ideal drug. Mayo Clin Proc. 1994;69:1069-1081.
91. 2c receptors. Br J Pharmacol. 1998;124:1781-1787.
92. Ko H-C, Lu R-B, Shiah I-S, Hwang C-C. Plasma free 3-methoxy-4- hydrophenylglycol predicts response to fluoxetine. Biol Psychiatry. 1997;41:774-781.
93. Lechin F, van der Dijs B, Benaim M. Benzodiazepines: tolerability in elderly patients. Psychother Psychosom. 1996;65:171-182.
94. Rabey JM, Oberman Z, Graff E, Korczyn AD. Decreased dopamine uptake into platelet storage granules in Gilles de la Tourette disease. Biol Psychiatry. 1995;38:112-115.
95. Elam M, Thoren P, Svensson TH. Locus coeruleus neurons and sympathetic nerves: activation by visceral afferents. Brain Res. 1986;375:117-125.
96. Tsukamoto K, Sved AF, Ito S, et al. Enhanced serotonin-mediated responses in the nucleus tractus solitarius of spontaneously hypertensive rats. Brain Res. 2000;863:1-8.
97. Koulu M, Saavedra JM, Niwa M, Linnoila M. Increased catecholamines metabolism in the locus coeruleus of young spontaneously hypertensive rats. Brain Res. 1986;369:361-364.
98. Mancia G, Grassi G, Parati G, Zanchetti A. The sympathetic nervous system in human hypertension. Acta Physiol Scand. 1997;640(suppl):117-121.
99. Lambert GW, Kaye DM, Thompsom JM, et al. Internal yugular venous spillover of noradrenaline and metabolites and their association with sympathetic nervous activity. Acta Physiol Scand. 1998;163:155-163.
100. Lechin F, van der Dijs B, Villa S, Lechin AE. Central nervous system (CNS) circuitry involved in blood pressure regulation. In: Lechin F, van der Dijs B, eds. Neurochemistry and Clinical Disorders: Circuitry of Some Psychiatric and Psychosomatic Syndromes. Boca Raton, FL: CRC Press; 1989:121-150.
101. Burchfield SR. The stress response: a new perspective. Psychosom Med. 1979;41:661-672.
102. Swedberg K, Brislow M, Cohn JN, et al. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation. 2002;105:1797-1803.
103. Abdallah H, Guyenet PG. Protypical imidazoline-1 receptor ligand monoxidine activates alpha-2 adrenoceptors in bulbo spinal neurons of the RVL. J Neurophysiol. 2000;83:766-776.
104. Wu M-F, Gulyani SA, Yau E, et al. Locus coeruleus neurons: cessation of activity during cataplexy. Neurosci. 1999;91:1389-1399.
105. Lechin F, Lechin ME, van der Dijs B. Plasma catecholamines and chronic congestive heart failure. Circulation. 2002;106:222.
106. Gillette RN, Punnen S, Krieger AJ, Sapru HN. Interdependence of rostral and caudal ventrolateral medullary areas in the control of blood pressure. Brain Res. 1984;321:169-174.
107. Lechin F, van der Dijs B, Lechin ME. Plasma neurotransmitters and functional illness. Psychother Psychosom. 1996,65:293-318.
108. Yazawa M, Ikeda SI, Ushiyama M, Yanagisawa N. Noradrenergic nerve fibers of the rectal mucosa in autonomic disorders: comparison of histochemical study with clinical severity and changes in plasma noradrenaline induced by standing. J Neurol Sci. 1991;104:222-229.
109. Page ME, Valentino RJ. Locus coeruleus activation by physiological challenges. Brain Res Bull. 1994;35:557-560.
110. Cedarbaum JM, Aghajanian GK. Noradrenergic neurons of the locus coeruleus: inhibition by epinephrine and activation by the alpha-antagonist piperoxane. Brain Res. 1976;112:413-419.
111. Engberg G, Elam M, Svensson TH. Effect of adrenaline synthesis inhibition on brain noradrenaline neurons in locus coeruleus. Brain Res. 1981;223:49-58.
112. Hokfelt T, Johansson O, Goldstein M. Central catecholamines neurons as revealed by immunochemistry with special reference to the adrenaline neurons. In: Bjorklund A, Hokfelt T, eds. Handbook of Neuroanatomy, Classical Transmitters in the CNS. New York, NY; Elsevier Science; 1984;2:157-276.
113. Petty MA, Reid JL. Changes in noradrenaline concentration in brain stem and hypothalamic nuclei during the development of renovascular hypertension. Brain Res. 1977;136:376-380.
114. Pancera P, Sansone S, Presciuttini B, et al. Autonomic nervous system dysfunction in sclerodermic and primary Raynaud's phenomenon. Clin Sci. 1999;96:49-57.
115. Hoeper MM, Galie N, Simonneau G, Rubin LJ. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165:1209-1216.
116. Lechin F, van der Dijs B, Lechin ME. Neuroautonomic, neuroendocrine and neuroimmune interactions. In: Lechin F, van der Dijs B, Lechin ME, eds. Neurocircuitry and Neuroautonomic Disorders. Reviews and Therapeutic Strategies. Basel, Switzerland; Karger; 2002:57-59.
117. Jarnicki AG, Fallon PG. T helper type-2 cytokine responses: potential therapeutic agents. Curr Opin Pharmacol. 2003;3:449-455.
118. Culebras A. The neurology of sleep. Neurology. 1992;42(suppl 6):6-8.
119. Ramage AG. Central cardiovascular regulation and 5-hydroxytryptamine receptors. Brain Res Bull. 2001;56:425-439.
120. Senba E, Matsunaga K, Tohyama M, Noguchi K. Stress-induced c-fos expresion in the rat brain: activation mechanism of sympathetic pathway. Brain Res Bull. 1993;31:329-344.
121. Nosjean A, Callera JC, Bonagamba L, et al. Serotonin receptor stimulation in the nucleus tractus solitarii activates non-catecholaminergic neurons in the rat ventrolateral medulla. Neuroscience. 2002;112:935-949.
122. Eddahibi S, Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. Respir Res. 2002;3:9.
123. Lesch KP. Molecular biology, and genetics of the serotonin transporter: psychobiological and clinical implications in serotoninergic neurons and 5-HT receptors in the CNS. In: Baumgarten HG, Gothert M, eds. Handbook of Experimental Pharmacology. Berlin, Germany: Springer; 1997.
124. Eddahibi S, Raffestin B, Pham I, et al. Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol. 1997;272:H1173-H1181.
125. Lechin F, van der Dijs B, Orozco B, et al. Increased levels of free serotonin in plasma of symptomatic asthmatic patients. Ann Allergy Asthma Immunol. 1996;77:245-253.
126. Lechin F. Asthma, asthma medication and autonomic nervous system dysfunction. Clin Physiol. 2001;21:723-724.
127. Lechin F, van der Dijs B, Lechin AE. Severe asthma and plasma serotonin. Allergy. 2002;57:258-259.
128. Lechin F. Central and plasma 5-HT, vagal tone and airways. Trends Pharmacol Sci. 2000;21:425-426.
129. Lechin F, van der Dijs B, Lechin AE. Tianeptine: a new exploratory therapy for asthma. Chest. 2004;125:348-349.
130. Dupont LJ, Pype JL, Demedts MG, et al. The effects of 5-HT on cholinergic contraction in human airways in vitro. Eur Respir J. 1999;14:642-649.
131. Cazzola M, Matera MG. 5-HT modifiers as a potential treatment of asthma. Trends Pharmacol Sci. 2000;21:13-15.
132. Strum JM, Junod AF. Radioautographic demonstration of 5-hydroxytryptamine-3H uptake by pulmonary endothelial cells. J Cell Biol. 1972;54:456-467.
133. Pype JL, Verleden GM, Demedts MG. 5/HT modulates noncholinergic contraction in guinea pig airways in vitro by prejunctional 5/HT1/like receptor. J Appl Physiol. 1994;77:1135-1141.
134. Spannhake EW, Levin JL, Mellion BT, et al. Reversal 5-HT-induced bronchoconstriction by PG12: distribution of central and peripheral actions. J Appl Physiol. 1980;49:521-527.
135. Cushley MJ, Wee LH, Holgate ST. The effect of inhaled 5-hydroxytryptamine (5-HT, serotonin) on airway caliber in man. Br J Clin Pharmacol. 1986;22:487-490.
136. Capron A, Joseph M, Ameisen JC, et al. Platelets as effectors in immune and hypersensitivity reactions. Int Arch Allergy Appl Immunol. 1987;82:307-312.
137. Cosgriff TM. Viruses and hemostasis. Rev Infect Dis. 1989;11(suppl 4):S672-S688.
138. Hechtman HB, Lonergan EA, Staunton HP, et al. Pulmonary entrapment of platelets during acute respiratory failure. Surgery. 1978;83:277-283.
139. Cazzola M, Matera MG, Rossi F. Bronchial hyperresponsiveness and bacterial respiratory infections. Clin Ther. 1991;13:157-171.
140. Dampney RA. The subretrofacial vasomotor nucleus: anatomical, chemical and pharmacological properties and role in cardiovascular regulation. Prog Neurobiol. 1994;42:197-227.
141. Hilaire G, Bou C, Monteau R. Rostral ventrolateral medulla and respiratory rhythmogenesis in mice. Neurosci Lett. 1997;224:13-16.
142. Lindsey BG, Arata A, Morris KF, et al. Medullary raphe neurons and baroreceptor modulation of the respiratory motor pattern in the cat. J Physiol. 1998;512:863-882.
143. Richard CA, Stremel RW. Involvement of the raphe in the respiratory effect of gigantocellular area activation. Brain Res Bull. 1990;25:19-23.
144. Huang Z-G, Subramanian SH, Balnave RJ, et al. Role of periaqueductal grey and nucleus tractus solitarius in cardiorespiratory function in the rat brainstem. Respir Physiol. 2000;120:185-195.
145. Holtman JR Jr, Dick TE, Berger AJ. Serotonin-mediated excitation of recurrent laryngeal and phrenic motoneurons evoked by stimulation of the raphe obscurus. Brain Res. 1987;417:12-20.
146. 1A receptors in the control of B-fibre cardiac and bronchoconstrictor vagal preganglionic neurons in anestethized cats. J Physiol. 2001;536:753-767.
147. Arita H, Ochiishi M. Opposite effect of 5-hydroxytryptamine on two types of medullary inspiratory neuron with distinct firing patterns. J Neurophysiol. 1991;66:285-292.
148. Skaburskis M, Shardonofsky F, Milic-Emili J. Effect of serotonin on expiratory pulmonary resistance in cats. J Appl Physiol. 1990;68:2419-2425.
149. Behan M, Brownfield MS. Age-related changes in serotonin in the hypoglosal nucleus of rat: implications for sleep-disordered breathing. Neurosci Lett. 1999;267:133-136.
150. Broqua P, Baudrie V, Laude D, Chaouloff F. Influence of the novel antidepressant tianeptine on neurochemical, neuroendocrinological, and behavioral effects of stress in rats. Biol Psychiatry. 1992;31:391-400.
151. Piñeyro G, Deveault L, Blier P, et al. Effect of acute and prolonged tianeptine administration on the 5-HT transporter: electrophysiological, biochemical and radiological binding studies in the rat brain. Naunyn-Schmiedeberg's Arch Pharmacol. 1995;351:111-118.
152. Lechin F, van der Dijs B, Lechin AE. Treatment of bronchial asthma with tianeptine. Methods Find Exp Clin Pharmacol. 2004;26:697-701.
153. Singh VK, Mehrotra S, Agarwal SS. The paradigm of Th1 and Th2 cytokines. Its relevance to autoimmunity and allergy. Immunol Res. 1999;20:147-161.
154. Salzet M, Vieau D, Day R. Crosstalk between nervous and immune systems through the animal kingdom: focus on opioid. Trends Neurosci. 2000;23:550-555.
155. Downing JEG, Miyan JA. Neural immunoregulation: emerging roles for nerves in immune homeostasis and disease. Immunol Today. 2000;21:281-289.
156. Lechin F, van der Dijs B, Lechin ME. Stress. In: Lechin F, van der Dijs B, Lechin ME, eds. Neurocircuitry and Neuroautonomic Disorders. Reviews and Therapeutic Strategies. Basel, Switzerland: Karger; 2002:18-22.
157. Lechin F, van der Dijs B, Orozco B, et al. Neuropharmacological treatment of refractory idiopathic thrombocytopenic purpura: roles of circulating catecholamines and serotonin. Thromb Haemost. 2004;91:1254-1256.
158. Lechin F, van der Dijs B. Platelet serotonin and thrombostasis. J Clin Invest. 2004; Available at http://www.jci.org - Letters. April 21.
159. Lechin F, van der Dijs B, Orozco B, et al. Elective stenting, platelet serotonin and thrombotic events. Platelets. 2004;15:462-463.
160. Lechin F, van der Dijs B. Platelet aggregation, platelet serotonin and pancreatitis. JOP. 2004;5:8001-8003.
161. Lechin F, van der Dijs B, Orozco B, et al. Neuropharmacological therapy of polycythemia vera: roles of circulating catecholamines and serotonin. Thromb Haemost. 2005;93:175-177.
162. Gobbi G, Mirandola P, Tazzari PL, et al. Flow cytometry detection of serotonin content and release in resting and activated platelets. Br J Haematol. 2003;121:892-896.
163. Dale GI, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Science. 2002;415:175-179.
164. Dominguez V, Govezensky T, Gevorkian G, Larralde C. Low platelet counts do not cause bleeding in an experimental model of immune thrombocytopenic purpura in mice. Haematologica. 2003;88:679-687.
165. Lechin F, van der Dijs B. Platelet activation and catheter intracoronary brachytherapy [online journal]. Heart. 2004; Available at http://heart. bmjjournals.com Read eLetters) July 1.
166. Lechin F, van der Dijs B, Orozco B, et al. Neuropharmacological therapy of the neuroendocrine carcinoid syndrome: report of two cases. J Appl Res. 2005;5:109-114.
167. Lechin F, van der Dijs B. Neuropharmacological therapy of carcinoid syndrome. Neuroendocrinology. 2005;81:137-138.
168. Lechin F, van der Dijs B, Lechin S, et al. Neurochemical, hormonal and immunological views of stress: clinical and therapeutic implications in Crohn's disease and cancer. In:Velazco M, ed. Recent Advances in Pharmacology and Therapeutics. International Congress Series vol. 839. Amsterdam, Netherlands: Excerpta Medica; 1989:57-70.
169. Lechin F, van der Dijs B, Lechin ME. Illustrations of some therapeutic results. In: Lechin F, van der Dijs B, Lechin ME, eds. Neurocircuitry and Neuroautonomic Disorders. Reviews and Therapeutic Strategies. Basel, Switzerland: Karger; 2002:75-94.
170. Krause SW, Gastpar R, Andreesen R, et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin Cancer Res. 2004;10:3699-3707.
171. Lechin F, van der Dijs B, Lechin AE. Natural killer cells activity and neuroimmunological treatment of cancer. Clin Cancer Res. 2004;10:8120-8121.